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Background: Although the proportion of cases of ac-
quired immunodeficiency syndrome related to intrave-
nous drug use has increased dramatically over the past
decade, there has been no longitudinal examination of
primary neurologic disease in this group.
Objective: To study the development of neurologic dis-
ease in human immunodeficiency virus (HIV)\p=m-\negative
and HIV-positive men and women who were intrave-
nous drug users over a 3.5-year period.
Design: Prospective observational cohort study.
Setting: Subjects were recruited from an infectious dis-
ease clinic at a New York City Hospital or from a metha-
done maintenance program.
Participants: Ninety-nine HIV-negative (62 men and
37 women) and 124 HIV-positive (85 men and 39 wom-
en) intravenous drug users volunteered.
Main Outcome Measure: The development of clini-
cally significant manifestations in six neurologic
domains.
Results: With multivariate adjustment for current
and past substance abuse, age, education, and head
injury, we examined the odds of developing HIV\x=req-\
related neurologic disease. Extrapyramidal signs and
reduced motor ability became increasingly apparent
over time in HIV-infected men as their CD4 cell count
declined and as the subjects developed the acquired
immunodeficiency syndrome. Fewer neurologic signs
were seen in the women.
Conclusions: The impact of HIV infection among in-
travenous drug users parallels that in homosexual men
and is independent of alcohol and other drug use.
(Arch Neurol. 1995;52:1174-1182)
THE PROPORTION of cases ofacquired immunodefi¬ciency syndrome (AIDS)related to intravenous druguse has increased dramati¬
cally over the past decade and is cur¬
rently estimated at 34%.13 Although a
number of studies4"6 have addressed the
neuropsychologic findings in intrave¬
nous drug users (IDUs) who were fol¬
lowed up for 1 year, no longitudinal ex¬
amination of the neurologic findings in
human immunodeficiency virus (HIV)-
infected IDUs has been reported.
In a cross-sectional analysis, we7 have
previously found that HIV-positive IDUs
had evidence of extrapyramidal signs (EPS)
and that the neurologic findings were more
severe in those with AIDS-related com¬
plex (ARC) than in those with few or no
systemic signs of illness. In this study, we
performed detailed prospective neuro¬
logic examinations biannually to address
the following questions: (1) Are there spe-
cific neurologie signs attributable to HIV
infection independent of the effects of sub¬
stance abuse, age, education, and history
of head injury with loss of conscious¬
ness? (2) Are there differences in the neu¬
rologic profiles in men and women? (3)
What is the relationship between neuro¬
logic outcomes and stage of illness and
immune status? (4) What is the relation¬




Demographic characteristics of the co¬
hort are presented in Table 2. The CD4
See Subjects and Methods
on next page
Deceased.
The affiliations of the
authors appear in the
"acknowledgment" section
on page 1181.
Downloaded From: http://archneur.jamanetwork.com/pdfaccess.ashx?url=/data/journals/neur/16380/ by a Columbia University User  on 06/13/2017
SUBJECTS AND METHODS
SUBJECTS
Two hundred twenty-three IDUs (99 HIV-negative and 124
HIV-positive) were recruited in late 1988 through 1989 to
participate in a 5-year follow-up study. These included 147
men (85 HIV-positive and 62 HIV-negative) and 76 women(39 HIV-positive and 37 HIV-negative). Subjects were re¬
cruited from the Harlem Hospital Infectious Disease Clinic(n=170) and from the St Luke's- Roosevelt Methadone Main¬
tenance Clinic (n=53) (both in New York, NY). Inclusion
and exclusion criteria and screening procedures have been
described elsewhere.8 All subjects were volunteers, and all
gave informed consent. All participants had used intrave¬
nous drugs at least 10 times since 1982 and met the Diag¬
nostic and Statistical Manual oj Mental Disorders, Revised
Third Edition9 criteria for substance abuse. All subjects who
entered the longitudinal phase were examined every 6
months for up to eight visits (a 3.5-year period).
ASSESSMENTS
At each visit, subjects received a standardized medical ex¬
amination to stage HIV severity, a neurologic assessment,
and a neuropsychologic assessment. Demographic infor¬
mation, substance abuse history, and history of head in¬jury with loss of consciousness were obtained. Laboratory
studies at each visit included complete blood cell count and
lymphocyte typing. Information on the prevalence of hu¬
man T-cell lymphotropic virus types I and II was obtained
at visit 2 only.
Medical Assessment
Physicians performed physical examinations targeted at HIV-
related symptoms and signs. During follow-up, subjects were
characterized as HIV-negative, HIV-positive but physi¬
cally asymptomatic, HIV-positive and mildly symptom¬
atic, symptomatic but not meeting the criteria for AIDS(ARC), and with AIDS. Nomenclature and staging reflect
the 1986 Centers for Disease Control (Atlanta, Ga) stag¬
ing system.10·11
Neurologic Assessment
Neurologic examinations were performed by neurologists who
were blind to the HIV status of the subjects. To maintain them
blind, the neurologic examinations were performed prior to
the elicitation of symptoms. A standard neurologic exami¬
nation was performed. Items from the motor portion of the
Unified Parkinson's Disease Rating Scale12 were included to
assess extrapyramidal function. Each neurologic sign was
coded separately so that individual signs could be examined
and factor scores could be created based on individual items.
Neurologic symptoms were elicited using the structured in¬
terview created by Price et al.13 Reliability of the neurologic
examination was good to excellent.14
The neurologic data were summarized in two ways.
First, an overall measure of neurologic disability was de¬
termined for each subject, based on the Kurtzke Disability
Status Scale for Multiple Sclerosis.15 This previously de¬
scribed scale16 reflects both the number of areas of neuro¬
logic dysfunction (ie, pyramidal tract, cerebellar area, and
brain stem) and the severity of impairment. A score of 3
or greater indicates a level of impairment that most neu¬
rologists would reliably detect and consider clinically
meaningful and would describe someone with moderate
neurologic disability who was fully ambulatory.
Neurologic data were also summarized in a factor analy¬
sis on selected items of the neurologic examination.7 Six
factors have proved stable over the eight visits and repre¬
sent major neurologic domains. Each factor was dichoto¬
mized at a level believed to indicate clinical significance,
rather than considering the factors as continuous vari¬
ables. Factors were dichotomized because, for example, it
is not clear that the difference between a score of 1 and 2
is the same as between 2 and 3 on the release reflexes fac¬
tor. It is also easier to interpret the odds of having clini¬
cally meaningful signs than to interpret the odds of devel¬
oping an increase of one point on a specific factor. The six
factors and the scores used to dichotomize them into high
and low are shown in Table 1.
Neuropsychologic Assessment
The neuropsychologic battery was created to capture a wide
range of deficits and has been previously reported.' To re¬
duce the number of test scores, six neuropsychologic fac¬
tors were constructed, based on those used in the analyses
of homosexual men.17 These included (1) memory: selec¬
tive reminding test total score18; (2) motor speed: grooved
pegboard19 (time to insert pegs with dominant hand); (3)
executive: odd man out total score20 and Trail B21 time; (4)
language: Controlled Oral Word Association Test (60 sec¬
onds for each of the letters C, F, and L) and animal nam¬
ing22; (5) attention: digit symbol age-scaled score25 and space
and letter cancellation time24; and (6) orientation: orien¬
tation score from Mini-Mental State examination.2' Sum¬
mary scores were calculated for each subject by transform¬
ing component scores into  scores based on the mean and
Continued on next page
cell count was significantly lower (P<.001) and the neu¬
rologic disability score was significantly higher (P<.01)
in HIV-positive subjects compared with HIV-negative sub¬jects. Men were significantly older (P<.05) but had sig¬
nificantly lower neurologic disability scores (P<.01) than
women, indicating that men had less neurologic disease
at baseline. Of note, the HIV-negative women had higher
mean disability scores at baseline than the HIV-negative
men; in fact, their scores were similar to those of the HIV-
positive men. Men were significantly more likely to be
substance abusers; the frequency of ethanol use for at least
20 years and heroin or cocaine use for at least 15 years was
significantly greater for men (P< .01 ). Reported long-term
substance abuse did not differ by HIV status at baseline.
Men were also significantly more likely to report head in¬jury with loss ofconsciousness than were women (P< .05).
None of the subjects were positive for human T-cell lym-
photropic virus type I. There was no difference in the hu¬
man T-cell lymphotropic virus type II seroprevalence among
HIV-negative and HIV-positive men and women.
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SD of the test scores of all subjects at the baseline visit. The
factor scores were the sum of the  scores that were ad¬
justed for direction and for measures within each factor and
were analyzed as continuous variables.
EVALUATION OF ALCOHOL
AND OTHER DRUG USE
Substance Abuse History
All subjects were systematically interviewed at each visit
about their alcohol and other drug usage. Use of all forms
of heroin, cocaine, benzodiazepines, hallucinogens, and
phencyclidine were queried. We created a variable to re¬
flect the length of time subjects used heroin, all forms of
cocaine, or alcohol. The number of years of drug use was
highly correlated with the age of the subjects, so the usage
variable included both age and years of drug use. Years of
illicit drug use were dichotomized into long (&15 years)
or short (<15 years), and alcohol use was also dichoto¬
mized into long (&20 years) or short (<20 years). If ei¬
ther alcohol or other drug use was considered long, the sub¬ject was considered to have a long history of substance abuse.
No women over age 40 years and no men over age 45 years
had a short history of alcohol or other drug use. There¬
fore, a variable with only three possible categories was cre¬
ated. Women were classified as age 40 years or younger with
short substance use, 40 years or younger with long sub¬
stance use, and over age 40 years with long substance use.
Women aged 40 years or younger with short substance abuse
were used as the reference group. Men were similarly di¬
vided into three age and substance abuse groups, using age
45 years or younger as a cut point. In this way, the pro¬
portion of subjects' lives during which they used alcohol
or other drugs was captured.
Recent Substance Abuse History
The frequency of substance abuse in the 6-month interval
prior to the assessment was dichotomized into high for
weekly or daily use and low for monthly or less frequent
use. Data on recent substance abuse were available only for
visits 2 through 7.
STATISTICAL ANALYSIS
The baseline characteristics of the HIV-positive and HIV-
negative subjects were analyzed using a two-way analysis
of variance for continuous variables and logistic analyses
for binary variables, with HIV status and gender as main
effects.
To take into account the multiple visits per subject and
the fact that the characteristics of a single individual over
time are likely to be correlated, a generalized estimating
equations approach26 was used. In this analysis, the re¬
peated measures for each subject (up to eight measures per
variable) are treated as a cluster. The generalized estimat¬
ing equation approach takes into account the status or chang¬
ing value of covariates and outcomes at each visit. It pro¬
vides estimates of the odds of the occurrence of an outcome
dependent on the values of covariates. The outcome vari¬
ables included the six neurologic domains and a modified
Disability Status Scale, as described above. Odds ratios (ORs),
rather than relative risks, were calculated because the analy¬
sis includes both prevalent cases, ie, those who have reached
the outcome at baseline, and incident cases.
Because of the significant differences in baseline age
and disability scores between men and women, as well as
the different pattern of substance abuse, data for women
and men were always analyzed separately.
The first set of analyses included either all women or
all men and examined the effect of HIV status on the odds
of developing each neurologic outcome, defined as a high
factor score. We also examined changes in these odds over
subsequent visits.
The second set of analyses, again considering women
and men separately, was restricted to the HIV-positive sub¬jects. The outcome variables (six neurologic domains and
measure of general neurologic disability) were examined
and adjusted for age, education, alcohol or other drug use,
and history of head injury. We included immune status(CD4 cell count) and stage of HIV infection as covariates
in two separate analyses of the HIV-positive women and
men. The CD4 cell count was treated as a categorical vari¬
able; subjects were classified as those having CD4 cell counts
of0.2X 109/L or less and those having 0.2X 109 to 0.5X 107L,
with those having a CD4 cell count of 0.5X 109/L or greater
as a reference group. This categorization was designed to
capture the subjects who would currently meet the 1992
Centers for Disease Control and Prevention criteria for AIDS,
ie, those with a CD4 cell count of 0.2X 109/L or less. Sub¬
jects were also classified into those satisfying the criteria
for ARC and those with AIDS, while those with mild symp¬
toms or no symptoms were considered the reference group.
In a third set of analyses, restricted to HIV-positive men
and women, the relationship between neurologic disabil¬
ity and neuropsychologic impairment was examined by a
linear regression model with repeated measures.
The use of zidovudine was not included in any of
the models because usage was not widespread and the
length of treatment was limited. Information on zidovu¬
dine use was available only from visits 2 through 7. Only
one subject reported zidovudine use at visit 2. By visit 3,
55 subjects reported having been treated with zidovu¬
dine, but only 16 subjects were taking zidovudine at that
visit. At visit 4, 35 subjects were taking zidovudine; at
visit 5, eight; at visit 6, four; and at visit 7, two subjects
were taking zidovudine.
None of the 124 HIV-positive subjects met the 1986
criteria for AIDS at baseline. A similar proportion of men
and women had no symptoms (27.1% men and 23.1%
women), mild symptoms (28.2% men and 15.4% wom¬
en), or met the criteria for ARC (44.7% men and 61.5%
women). The proportion of men and women with a CD4
cell count of 0.2X 109/L or less was also similar (25.9%
men and 23.1% women).
There were 32 deaths (22 men and 10 women), and
32 subjects (24 men and eight women) were unavail¬
able for follow-up (they did not complete all eight vis¬
its, but they did not die) among the HIV-positive sub¬jects. Among HIV-negative subjects, there were four deaths
and 35 subjects were unavailable for follow-up (19 men
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and 16 women). One HIV-negative woman seroconver-
ted during follow-up and subsequently died; she was
counted among the HIV-positive subjects who died. Two
of the HIV-positive subjects died soon after completing
their eighth visit and were considered among those who
died. Baseline CD4 cell counts in men (mean count±SD,[0.23±0.18]X107U and in women (mean count±SD,[0.23±0.23] X107L) who died differed significantly from
those in HIV-negative men (mean count±SD,[1.12±0.32]X107L), HIV-negative women (mean
count±SD,[1.15±0.30]Xl 09/L), and HIV-positive sub-
jects who were unavailable for follow-up but were not
known to have died (mean count±SD, [0.49±0.25]
X107L in men and [0.36±0.17] X107L in women).
At visit 8, after 3.5 years of follow-up, there were
66 HIV-positive subjects (41 men and 25 women) and
55 HIV-negative subjects (38 men and 17 women). Two


























All cranial nerve signs
Rigidity in all limbs,
bradykinesia, salivation,
gait, hypomimia, speech,




*Each item is graded as 0 or 1, and the maximum score is the number
of items.
Men had 5.4 visits on average compared with 5.5 visits
for women.
PROGRESSION OF NEUROLOGIC FACTORS
AND SUMMARY VARIABLES OVER TIME
To assess the relationship between the development of
neurologic impairment and severity of HIV infection,
HIV-positive subjects were classified into four groups(asymptomatic, mildly symptomatic but insufficient for
a diagnosis of ARC, ARC, and AIDS) at the visit when
they first had a high score above the cut point on any
individual neurologic factor. Similarly, they were classi¬
fied by CD4 cell count (<0.2XI07L, 0.2 to 0.5X107L,
and &0.5X107L) when they first demonstrated a sig¬
nificant neurologic end point (Table 3). Neurologic
end points were reached by subjects at all stages of ill¬
ness, but the majority of subjects reaching these end
points had ARC. Women were less immunocompro-
mised than men when they first developed EPS (57.9%
of the women had a CD4 cell count between 0.2X10"
and 0.5X107L), while 39.1% of the men developed EPS
when their CD4 cell count was in the 0.2X10° to
0.5X10l>/L range, although this was not significantly
different. Approximately one third of the men and
women had a CD4 cell count of 0.2X 10"/L or less when
they developed generalized neurologic disability.
LOGISTIC REGRESSION
WITH REPEATED MEASURES
HIV-Positive vs HIV-Ncgative Women
The independent effects of HIV status on the develop¬
ment of high scores in the neurologic domains were ex¬
plored with adjusting for confounders such as educa¬
tion, history of head injury with loss of consciousness,
and the age and substance abuse variable.
Certain neurologic outcomes were independently at¬
tributable to history of substance abuse. Subjects 40 years
of age or younger with a long history of substance abuse
were significantly more likely to have high factor scores
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*HIV indicates human immunodeficiency virus; LOC, loss of consciousness. Values are either mean±SD or number (percent).
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Table 3. Severity of HIV Infection and Immune Status at Visit When Neurologic Outcome is First Demonstrated
No. (%) ot Subjects With Outcome
HIV Infection Severity CD4 Cell Count, x109/L






Extrapyramidal signs a2 2(4.3) 7(15.2) 33(72.7) 4(8.7)
Release reflexes >3 2(11.1) 3(16.7) 13(72.2) 0(0.0)
Neurologic disability s3 4(6.7) 5(21.7) 40(66.7) 3(5.0)
Women
Extrapyramidal signs >2 3(15.8) 1(5.3) 12(63.2) 1(5.3)
Release reflexes a3 2(20.0) 1(10.0) 6(60.0) 1(10.0)
Neurologic disability >3 7(23.3) 3(10.0) 17(56.7) 1(3.3)
2(10.5)
2 (6.7)
7(15.2) 18(39.1) 18(39.1) 3(6.5)
6 (33.3) 6 (33.3) 5 (27.8) 1 (5.6)







5 (26.3) 1 (5.3)
4 (40.0) 0 (0.0)







*HIV indicates human immunodeficiency virus: AIDS, acquired immunodeficiency syndrome; and ARC, AIDS-related complex.
on fine limb movements (OR, 2.5; 95% confidence in¬
terval [CI], 1.3 to4.8), EPS (OR, 3.3; 95% CI, 1.1 to 9.7),
sensory abnormalities (OR, 4.1; 95% CI, 1.8 to 9.5), and
release reflexes (OR, 3.7; 95% CI, 1.1 to 12.5) than those
40 years of age or younger with a short history of sub¬
stance abuse. Subjects older than 40 years of age with a
long history of substance abuse were more likely to have
greater neurologic disability (scored as S3) (OR, 4.3; 95%
CI, 1.9 to 9.6), high EPS scores (OR, 5.7; 95% CI, 2.2 to
14.6), and sensory abnormalities (OR, 3.0; 95% CI, 1.4
to 6.5) than subjects 40 years of age or younger with a
short history of substance abuse.
Recent alcohol or other drug abuse (6 months prior
to interval), dichotomized into high and low, was not
significantly related to the development of any of the
neurologic outcomes.
Education was negatively correlated with abnor¬
malities of fine limb movements, EPS, sensory abnor¬
malities, and neurologic disability. Women with a his¬
tory of head injury were twice as likely to have cranial
nerve abnormalities (OR, 2.06; 95% CI, 1.1 to 4.0). At
every visit, HIV-positive women were 2.4 times more likely
to have neurologic disability (scored as ^3) than were
HIV-negative women, after adjusting for the indepen¬
dent effects of age, education, history of head injury, and
substance abuse. No HIV by length of follow-up inter¬
actions was observed, suggesting that, over time, HIV-
positive women were no more likely to develop high fac¬
tor scores than were HIV-negative women.
HIV-Positive vs HIV-Negative Men
The 147 HIV-positive and HIV-negative men were analyzed
similarly. As in the women, there were neurologic signs in¬
dependently attributable to substance abuse. Men 45 years
ofage or younger with longtime substance abuse were more
likely to have fine limb movement abnormalities (OR, 2.3;
95% CI, 1.3 to 4.0) than were men 45 years ofage or younger
with a short history of substance abuse. Men older than 45
years ofage with longtime substance abuse were significantly
more likely to have cranial nerve abnormalities (OR, 3.1; 95%
CI, 1.5 to 6.3), fine limb movement abnormalities (OR, 2.7;
95% CI, 1.5 to 5), and release reflexes (OR, 10.0; 95% CI,
1.2 to 86.7) than were men 45 years ofage or younger with
a short history of substance abuse.
As in the women, no relationship between recent
alcohol or other drug use and the neurologic domains
was seen, except for neurologic symptoms. Those with
high recent alcohol or other drug use were more likely
to report symptoms than were those with low recent al¬
cohol or other drug use (OR, 1.76; 95% CI, 1.06 to 2.94).
Education was inversely correlated with EPS, ab¬
normalities of fine limb movements, and global neu¬
rologic impairment. As with the women, men with a
history of head injury with loss of consciousness were
twice as likely to have cranial nerve abnormalities (OR,
2.0; 95% CI, 1.3 to 3.0). Over time, both HIV-positive
and HIV-negative men were likely to develop neuro¬
logic disability (scored as >3) (OR, 1.4; 95% CI, 1.2 to
1.6) and to have sensory abnormalities (OR, 1.6; 95% CI,
1.4 to 1.8). At each visit, HIV-positive men had a higher
likelihood of having a neurologic disability (OR, 1.9; 95%
CI, 1.1 to 3.2) and were more likely to have cranial nerve
abnormalities (OR, 1.5; 95% CI, 1.0 to 2.3) and fine limb
movement abnormalities (OR, 1.8; 95% Cl, 1.2 to 2.8)
than HIV-negative men. Over the course of follow-up,
HIV-positive men were more likely to report HIV-
related symptoms than were HIV-negative men (OR, 1.4;
95% CI, 1.1 to 1.8) and were more likely to have EPS than
were HIV-negative men (OR, 1.6; 95% CI, 1.2 to 2.3)(Figure).
HIV-Positive Women Only
Analysis was then restricted to the 43 HIV-positive women(Table 4). Four women seroconverted during the fol¬
low-up period. They were included within the HIV-
positive group at the visit when they were first deter¬
mined to be HIV-positive. In the first analysis, covariates
included in the model were age at each visit, education,
history of head injury, and CD4 cell count (^0.2X109
and 0.2X10" to 0.5X109/L, with a CD4 cell count of
>0.5X 109/L as a reference group). Recent substance abuse
was initially included as a covariate in the model and was
not related to the development of any of the neurologic
outcomes. Because information was available for only vis¬
its 2 through 7, which resulted in a smaller data set, this
variable was not included in the final model. History of
substance abuse was not included in the model because
it was highly correlated with age.
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Proportion (%) of male intravenous drug users (IDUs) on each visit who
have extrapyramidal signs: crude vs modeled human immunodeficiency
virus (HIV). Plus sign indicates positive; minus sign, negative.
By adjusting for the effects of age, education, and
history of head injury, the odds of developing signifi¬
cant EPS and cranial nerve signs were increased in women
with a CD4 cell count of 0.2 X107L or less compared with
those with a CD4 cell count of 0.5X 107L or greater. By
adjusting for age, education, or head injury, women with
AIDS (1986 definition) were over five times as likely to
have a neurologic disability and 11 times as likely to have
neurologic symptoms than were women with no symp¬
toms or mild symptoms. Women with AIDS were sig¬
nificantly more likely to have neurologic disability (scored
as S3) than were women with ARC (P<.05). Compari¬
son ofwomen who had ARC with those who had no symp¬
toms or mild symptoms revealed no differences.
Relationship of Neurologic and
Neuropsychologic Outcomes
The presence or development of neurologic disability(scored as S3) was associated with poorer performance
on the language and motor speed factors (P<.05) and
weakly associated with the memory (P<.07) and atten¬
tion (P<.06) factors.
HIV-Positive Men Only
Eighty-six HIV-positive men, including two men who se-
roconverted during the follow-up period, were in¬
cluded in an analysis identical to that done for the HIV-
positive women (Table 5). In the first model, covariates
included age, education, history of recent substance abuse,
history of head injury with loss of consciousness, and CD4
cell count (categories <0.2X109 and 0.2 to 0.5X107L
compared with the >0.5X109/L category as a refer¬
ence). Recent substance abuse was associated only with
the high neurologic symptom scores (OR, 1.7; 95% CI,
1.1 to 1.4). In the final model, excluding recent sub¬
stance abuse, CD4 cell counts between 0.2X109/L and
0.5X 10'/Land a CD4 cell count of 0.2X 109/L or less were
associated with EPS, fine limb movement abnormali¬
ties, sensory impairment, and significant neurologic dis¬
ability compared with those with a CD4 cell count of
0.5 X10Q/L or greater. None of the other neurologic out-
comes were associated with low CD4 cell count. In the
second analysis, HIV stage was substituted for the CD4
cell count as a covariate. Men with ARC or AIDS had a
greater likelihood of having neurologic disability symp¬
toms, fine limb movement abnormalities, and EPS than
did men with no symptoms or with mild symptoms. Men
with AIDS were over nine times more likely to have neu¬
rologic disability than were men with no symptoms or
with mild symptoms and were also more likely to have
neurologic complaints. Only the OR for generalized neu¬
rologic disability was significantly higher for those with
AIDS than ARC.
Relationship of Neurologic and
Neuropsychologic Outcomes
There was a significant association between the devel¬
opment of neurologic disability and poor performance
on memory, executive function, language, attention, and
motor speed factors.
COMMENT
RELATIONSHIP BETWEEN SUBSTANCE ABUSE
AND HIV INFECTION IN WOMEN AND MEN
Determining the neurologic signs and symptoms attrib¬
utable to HIV-1 infection in IDUs poses challenges not
apparent in the analysis of HIV infection in homosexual
and bisexual men. Intravenous drug users may be im-
munosuppressed even in the absence of HIV infection.27
The proportion of women and minorities represented
among IDUs has led to a redefinition of AIDS-defining
illness2 to include recurrent bacterial pneumonia, pul¬
monary tuberculosis, and cervical carcinoma to better de¬
pict the spectrum of illness in this risk group. Polysub-
stance abuse, the high frequency of reported head injury,
and concomitant nutritional deficiencies might make it
more likely to observe neurologic impairment in IDUs
than in homosexual or bisexual men and more difficult
to discern the independent effects of HIV on the ner¬
vous system. Furthermore, male and female IDUs may
have different neurologic profiles. This might reflect dif¬
ferences in the type and frequency of substance abuse and
the pattern of substance abuse, once systemic illness is
evident.
In this sample, women were more likely to reduce
their drug use when they developed AIDS. The CD4 cell
counts may not accurately reflect the degree of illness in
women compared with men. In an analysis of the CD4
cell counts at which 50% of HIV-infected but AIDS-free
IDUs had ARC based on three biannually measured CD4
cell counts in this cohort, female IDUs had a median CD4
cell count of 0.76X 107L compared with 0.42X 107L in
male IDUs, suggesting that the CD4 cell count might not
accurately reflect the extent of systemic illness, particu¬
larly in female IDUs.28 Our findings of a higher fre¬
quency of women first presenting with significant EPS
when the CD4 cell count was in the 0.2 to 0.5X 109/L range
compared with men supports the notion that women may
present with neurologic illness at an earlier stage of im-
munocompromise than men. It is unlikely that this is at-
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Table 4. Odds Ratios for the Development of Neurologic Outcomes in HIV-Positive Women Only*
Outcome Variables
Odds Ratios (95% CI)









































*HIV indicates human immunodeficiency virus; CI, confidence interval; AIDS, acquired immunodeficiency syndrome; and ARC, AIDS-related complex.
fP<. 05: adjusted for age, education, and head injury.
Table 5. Odds Ratios for the Development of Neurologic Outcomes in HIV-Positive Men Only*
Odds Ratios (95% CI)
CD4 Cell Count, x107L HIV Stage
 - r~-1
Outcome Variables 0.2-0.5 0.2 ARC AIDS
Neurologic disability 2.0 (1.1-3.7)f 3.0 (1.6-5.7)f 2.2(1.3-3.8)1 9.3(2.0-43.6)1
Symptoms 1.2(0.6-2.2) 1.3(0.5-2.9) 2.6 (1.4-4.8)t 4.0(1.1-14.7)t
Fine limb movements 1.7(1.1-2.7)1 1.8 (1.0-3.1 )t 2.0 (1.1-3.7)t 2.6(0.8-8.3)
Extrapyramidal signs 2.9(1.3-6.7)1 3.8(1.6-9.0)1 2.9(1.4-5.8)1 3.6(1.1-12.2)1
Cranial nerve 0.8(0.4-1.6) 0.9(0.5-1.7) 1.6(0.9-2.9) 0.9(0.4-2.3)
Sensory abnormalities 2.1(1.1-3.8)1 1.3(0.7-2.4) 1.0(0.6-1.8) 1.4(0.4-4.8)
Release reflexes 1.1(0.5-2.4) 0.7(0.2-2.1) 1.1(0.4-3.1) 1.5(0.3-6.7)
*HIV indicates human immunodeficiency virus: CI, confidence interval: AIDS, acquired immunodeficiency syndrome; and ARC, AIDS-related complex.
fP<. 05; adjusted for age, education, and head injury.
tributable to selective early mortality in men. Baseline CD4
cell counts were similar in men and women overall.
The baseline CD4 cell counts of men and women who
were eventually unavailable for follow-up or who died
were similar. The numbers of visits for men and
women were almost identical.
Progression of neurologic illness may follow a dif¬
ferent course in men and women. This issue can only be
properly addressed in a matched analysis comparing men
and women with similar age, immunologie status, and
stage of illness, resulting in a much smaller sample size.
This will be reported separately.
Several important observations emerged from the
longitudinal follow-up of these 223 IDUs. Human im¬
munodeficiency virus-positive women were more likely
to have neurologic impairment than were HIV-negative
women, independent of the effects of age, education, head
injury, and drug and alcohol use. Women with a CD4
cell count of 0.2X 109/L or less were over six times as likely
to have EPS and twice as likely to have cranial nerve ab¬
normalities compared with those with a CD4 cell count
of 0.5 X109/L or greater, while women with AIDS (1986
definition) were over five times as likely to have global
neurologic impairment and over 11 times as likely to have
neurologic symptoms as were HIV-infected women with
no symptoms or with mild symptoms. Findings in the
men were more varied. Compared with HIV-negative men,
HIV-positive men were more likely to have a neurologic
disability, fine limb movement abnormalities and cra¬
nial nerve abnormalities, and, over time, EPS and neu¬
rologic symptoms were more likely to occur in HIV-
positive men than in HIV-negative men. In men, there
was a clear association between systemic illness (de¬
fined clinically as ARC or AIDS) and the odds of having
fine limb movement abnormalities, EPS, and neurologic
symptoms. A declining CD4 cell count was also associ¬
ated with the presence of neurologic signs. Because these
relationships held after adjusting for age (correlated with
substance use history), education, and head injury, we
believe that these neurologic findings are attributable to
HIV infection and not to substance abuse. In both men
and women, neurologic impairment was associated with
neuropsychologic impairment in the domains of
motor speed and language, while men also demon¬
strated an association with executive function,
memory, and attention.
NEUROLOGIC MANIFESTATIONS
OF CHRONIC SUBSTANCE ABUSE
Tremor and parkinsonism are well-known complica¬
tions of alcohol and opioid abuse, notably MPTP (1-
methyl-4-phenyl-l,2,3,6-tetrahydropyridine),29 while tics
and dystonia are more often associated with cocaine use.30
After controlling for substance abuse, parkinsonism and
fine limb movement abnormalities were a prominent fea-
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ture, particularly in HIV-infected men. There was no as¬
sociation between recent substance abuse and these
outcomes.
SELECTIVE VULNERABILITY OF THE BASAL
GANGLIA IN ADVANCED HIV INFECTION
The prominent EPS and fine limb movement abnormali¬
ties seen in HIV-positive men and women, particularly
those with greater systemic illness or immunocompro-
mise, parallel our findings in 207 homosexual men who
were followed up prospectively over 4.5 years,14 suggest¬
ing that HIV has similar effects on the nervous system,
regardless of risk group. There are several lines of evi¬
dence in the neuropathologic and radiologie literature
to support the idea that the basal ganglia are particu¬
larly vulnerable in HIV infection. Quantitative mag¬
netic resonance imaging analysis has shown a stronger
association of the bicaudate ratio, a measure of atrophy
in the caudate nucleus with HIV dementia, than the ven¬
tricle-brain ratio, a measure of generalized atrophy.31 Simi¬
larly, HIV-infected patients with dementia could be dis¬
tinguished from patients without dementia based on
smaller basal ganglia volumes, after correction for intra¬
cranial volume.32 These changes have not been repli¬
cated in HIV-infected subjects with no symptoms or with
mild symptoms when nonquantitative measures of atro¬
phy with magnetic resonance imaging were used.3334 In
both children33 and adults,3'1 neuropathologic evidence
of inflammatory infiltrates predominate in the basal gan¬
glia and are accompanied by diffuse white matter astro¬
cytosis. The possibility that HIV-1-associated neuronal
damage might be mediated via the NMDA (N-methyl-D-
aspartate) receptor37 coupled with the demonstration of
increased quinolinate in the cerebrospinal fluid of pa¬
tients with dementia38 also points to the basal ganglia as
a location for HIV-mediated damage. Therefore, the as¬
sociation of extrapyramidal features and fine limb move¬
ment abnormalities in immunosuppressed, systemi-
cally ill HIV-positive IDUs is not surprising, although
impairment in fine alternating movement might also re¬
flect cortical involvement, especially given the high fre¬
quency of head injury.
There are some limitations to this study. We could
not determine whether those who are immunocompro-
mised gradually worsen neurologically or whether there
is a sudden decline in neurologic function when a
certain immunologie status is reached.
The study was designed to describe the relation¬
ship between neurologic, neuropsychologic, and medi¬
cal findings early in the course of HIV infection. Few sub¬jects reached the end points of severe neurologic
impairment (eg, dementia) over the 3.5-year period. The
differences between HIV-positive and HIV-negative men
and women may be underestimated because HIV-
positive subjects were often not examined when they
became extremely ill, and only subjects who were am¬
bulatory were examined.
Because the incidence of HIV-associated neuro¬
logic illnesses is increased in those with a CD4 cell count
under 0.1X107L and antiretroviral use does not pro¬
vide protection against the development of dementia and
may actually worsen peripheral neuropathy, it is impor¬
tant to be aware of these findings in drug users.39 As HIV-
infected individuals live longer, even in the setting of
greater immunocompromise, the neurologic manifesta¬
tions of HIV infection in this rapidly expanding popu¬
lation are bound to increase.
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